Humana Inc (NYSE:HUM) – Analysts at Oppenheimer upped their Q2 2018 earnings estimates for Humana in a report released on Wednesday. Oppenheimer analyst M. Wiederhorn now expects that the insurance provider will earn $4.12 per share for the quarter, up from their prior forecast of $3.46. Oppenheimer currently has a “Outperform” rating and a $305.00 target price on the stock. Oppenheimer also issued estimates for Humana’s Q3 2018 earnings at $3.99 EPS, Q4 2018 earnings at $2.44 EPS, FY2018 earnings at $13.73 EPS, Q1 2019 earnings at $3.82 EPS, Q2 2019 earnings at $4.91 EPS, Q3 2019 earnings at $4.77 EPS and FY2019 earnings at $16.50 EPS.
HUM has been the topic of a number of other reports. BMO Capital Markets raised their price target on Humana from $290.00 to $300.00 and gave the stock an “outperform” rating in a research note on Friday, November 10th. Royal Bank of Canada restated a “sector perform” rating and issued a $242.00 price target (down from $245.00) on shares of Humana in a research note on Thursday, November 9th. Zacks Investment Research downgraded Humana from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 19th. Morgan Stanley lowered their target price on Humana from $276.00 to $270.00 and set an “overweight” rating on the stock in a research report on Thursday, November 9th. Finally, Deutsche Bank lifted their target price on Humana from $259.00 to $270.00 and gave the company a “hold” rating in a research report on Friday. Eight research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $269.68.
Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, February 7th. The insurance provider reported $2.06 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.00 by $0.06. The firm had revenue of $13.19 billion for the quarter, compared to the consensus estimate of $13.14 billion. Humana had a return on equity of 16.13% and a net margin of 4.55%. The company’s revenue for the quarter was up 2.4% on a year-over-year basis. During the same period last year, the business posted $2.34 EPS.
Large investors have recently bought and sold shares of the business. WFG Advisors LP raised its holdings in Humana by 4.5% during the second quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock valued at $113,000 after acquiring an additional 20 shares during the period. Fieldpoint Private Securities LLC bought a new stake in Humana during the third quarter valued at about $115,000. ClariVest Asset Management LLC bought a new stake in Humana during the third quarter valued at about $144,000. Daiwa SB Investments Ltd. raised its holdings in Humana by 44.9% during the fourth quarter. Daiwa SB Investments Ltd. now owns 710 shares of the insurance provider’s stock valued at $176,000 after acquiring an additional 220 shares during the period. Finally, Virtu Financial LLC bought a new stake in Humana during the fourth quarter valued at about $204,000. 94.39% of the stock is currently owned by institutional investors and hedge funds.
In other Humana news, VP Timothy S. Huval sold 1,382 shares of the firm’s stock in a transaction dated Tuesday, December 19th. The stock was sold at an average price of $246.04, for a total transaction of $340,027.28. Following the sale, the vice president now directly owns 11,557 shares of the company’s stock, valued at $2,843,484.28. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Jody L. Bilney sold 7,054 shares of the firm’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $247.89, for a total value of $1,748,616.06. Following the sale, the senior vice president now directly owns 11,704 shares in the company, valued at $2,901,304.56. The disclosure for this sale can be found here. Over the last three months, insiders have sold 10,115 shares of company stock worth $2,501,627. Insiders own 0.80% of the company’s stock.
The business also recently announced a quarterly dividend, which will be paid on Friday, April 27th. Investors of record on Friday, March 30th will be given a dividend of $0.50 per share. The ex-dividend date is Wednesday, March 28th. This is an increase from Humana’s previous quarterly dividend of $0.40. This represents a $2.00 annualized dividend and a yield of 0.75%. Humana’s payout ratio is 9.59%.
Humana announced that its board has approved a share buyback plan on Thursday, December 14th that allows the company to buyback $3.00 billion in outstanding shares. This buyback authorization allows the insurance provider to purchase shares of its stock through open market purchases. Shares buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.
TRADEMARK VIOLATION WARNING: “Q2 2018 EPS Estimates for Humana Inc (HUM) Boosted by Analyst” was reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/12/q2-2018-eps-estimates-for-humana-inc-hum-boosted-by-analyst.html.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.